Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease
British Journal of Ophthalmology · 2025
DOI: 10.1136/bjo-2024-325527 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Ophthalmology, 2025. Verfasst von Tatiana R Rosenblatt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA trosenblatt@meei.harvard.edu. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Exophthalmos, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Prior studies of teprotumumab for thyroid eye disease report proptosis reduction in millimetres, which does not fully capture teprotumumab’s clinical effect since a given number of millimetres change can be of variable impact depending on patients’ degree of pre-treatment proptosis. In this retrospective study analysing proptosis change as a percentage of pre-treatment proptosis among 119 patients, 208 (87.4%) eyes of 110 patients had proptosis reduction averaging 14.4% (range 2.2–40.5%) of their pre-treatment proptosis, or 3.3 mm (range 0.5–10.0 mm). Reporting proptosis reduction as a percentage of pre-treatment proptosis provides a better understanding of teprotumumab’s clinical impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA trosenblatt@meei.harvard.edu.
- Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
Zitieren
APA
Rosenblatt, T. R., Chiou, C. A., Yoon, M. K., Lee, N. G., Wolkow, N., & Freitag, S. K. (2025). Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease. British Journal of Ophthalmology. https://doi.org/10.1136/bjo-2024-325527
Vancouver
Rosenblatt TR, Chiou CA, Yoon MK, Lee NG, Wolkow N, Freitag SK. Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease. British Journal of Ophthalmology. 2025. doi:10.1136/bjo-2024-325527
BibTeX
@article{Rosenblatt2025,
author = {Rosenblatt, Tatiana R and Chiou, Carolina A and Yoon, Michael K and Lee, Nahyoung Grace and Wolkow, Natalie and Freitag, Suzanne K},
title = {Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease},
journal = {British Journal of Ophthalmology},
year = {2025},
doi = {10.1136/bjo-2024-325527}
}
EUVIMED